Export 5 results:
Author Title [ Type(Desc)] Year
Filters: Author is Dekker, Cornelia L  [Clear All Filters]
Journal Article
R. W. Frenck, Belshe, R., Brady, R. C., Winokur, P. L., Campbell, J. D., Treanor, J., Hay, C. M., Dekker, C. L., Walter, E. B., Cate, T. R., Edwards, K. M., Hill, H., Wolff, M., Leduc, T., and Tornieporth, N., “Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.”, Vaccine, vol. 29, no. 34, pp. 5666-74, 2011.
D. I. Bernstein, Edwards, K. M., Dekker, C. L., Belshe, R., Talbot, H. K. B., Graham, I. L., Noah, D. L., He, F., and Hill, H., “Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.”, J Infect Dis, vol. 197, no. 5, pp. 667-75, 2008.
L. A. Jackson, Chen, W. H., Stapleton, J. T., Dekker, C. L., Wald, A., Brady, R. C., Edupuganti, S., Winokur, P., Mulligan, M. J., Keyserling, H. L., Kotloff, K. L., Rouphael, N., Noah, D. L., Hill, H., and Wolff, M. C., “Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.”, J Infect Dis, vol. 206, no. 6, pp. 811-20, 2012.
B. C Creech, Dekker, C. L., Ho, D., Phillips, S., Mackey, S., Murray-Krezan, C., Pau, M. Grazia, Hendriks, J., Brown, V., Dally, L. G., Versteege, I., and Edwards, K. M., “Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.”, Hum Vaccin Immunother, vol. 9, no. 12, pp. 2548-57, 2013.
C. Carter, Houser, K. V., Yamshchikov, G. V., Bellamy, A. R., May, J., Enama, M. E., Sarwar, U., Larkin, B., Bailer, R. T., Koup, R., Chen, G. L., Patel, S. M., Winokur, P., Belshe, R., Dekker, C. L., Graham, B. S., and Ledgerwood, J. E., “Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.”, PLoS One, vol. 14, no. 9, p. e0222178, 2019.